Skip to content

Study on Mechanisms of Changes in Liver Disease and Sex Steroid Metabolism During Weight Loss

Study on Mechanisms of Changes in Liver Disease and Sex Steroid Metabolism During Weight Loss

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02964780
Acronym
SMELSS
Enrollment
90
Registered
2016-11-16
Start date
2016-01-19
Completion date
2020-05-05
Last updated
2021-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The main objective of the study is to gain insight in the early dynamics and mechanisms of recovery of liver disease and sex steroid metabolism during weight loss in obese men and women and to investigate whether surgical weight loss has differential effects as compared to weight loss with life style measures. In addition, we want to evaluate the postprandial hypoglycemic reactive syndrome (PPHRS) in these patients using a standard chewable meal. Secondary objectives are investigating determinants for the changes in sex steroids, liver disease and PPHRS. Possible determinants to be investigated are adipocytokine secretion patterns, body composition, resting metabolism rate, weight loss per se and changes in fat distribution, parameters of fatty acid metabolism, … .

Interventions

PROCEDUREGastric bypass surgery
BEHAVIORALConservative weight loss program

Sponsors

University Ghent
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Informed consent obtained * BMI \> 35 kg/m²

Exclusion criteria

* Primary or secondary hypogonadism due to genetic causes (Kallman syndrome etc.), tumors, infiltrative diseases, infections, pituitary apoplexy, trauma, critical illness, chronic systemic illness or intentional. * Type 2 Diabetes Mellitus treated with insulin or GLP-1 analogues * Current or recent use of insulin, corticosteroids, opiates (on a daily basis), growth hormones, androgen- or estrogen analogs, levothyroxine, anti-retroviral drugs or antipsychotics * Cancer (within \< 5 years) * High-grade malignancies * Serious co-morbidities such as renal, hepatic of cardiac failure * Known or suspected abuse of alcohol or narcotics * Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in sex steroidsBaseline, 3 weeks, 6 weeks, 6 months, 1 year.The change in sex steroids will be compared between the conservative and the gastric bypass group.
Change from baseline in liver fatBaseline, 6 months, 1 yearThe change in liver steatose will be compared between the conservative and the gastric bypass group
Correlation in changes in liver fat en changes in sex steroidsbaseline, 6 months, 1 year

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026